Cargando…
Pulmonary hypertension associated mortality in the United States from 2003 to 2020: an observational analysis of time trends and disparities
BACKGROUND: Pulmonary hypertension (PH) is an independent risk factor for morbidity and mortality. In the last two decades, significant advances have been made in management of World Health Organization (WHO) group 1 PH. However, there are no approved targeted pharmacotherapies for PH secondary to l...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10323561/ https://www.ncbi.nlm.nih.gov/pubmed/37426148 http://dx.doi.org/10.21037/jtd-22-1468 |
_version_ | 1785068973649297408 |
---|---|
author | Singh, Harpreet Agarwal, Lipisha Jani, Chinmay Bhatt, Padmanabh Hartley, Adam Shalhoub, Joseph Kurman, Jonathan S. Al Omari, Omar Ahmed, Alaaeldin Marshall, Dominic C. Salciccioli, Justin D. |
author_facet | Singh, Harpreet Agarwal, Lipisha Jani, Chinmay Bhatt, Padmanabh Hartley, Adam Shalhoub, Joseph Kurman, Jonathan S. Al Omari, Omar Ahmed, Alaaeldin Marshall, Dominic C. Salciccioli, Justin D. |
author_sort | Singh, Harpreet |
collection | PubMed |
description | BACKGROUND: Pulmonary hypertension (PH) is an independent risk factor for morbidity and mortality. In the last two decades, significant advances have been made in management of World Health Organization (WHO) group 1 PH. However, there are no approved targeted pharmacotherapies for PH secondary to left-sided heart diseases or chronic hypoxic lung diseases which are thought to account for more than 70–80% of the disease burden. No recent investigation has analyzed and compared the mortality burden related to WHO group 1 PH with the mortality burden with WHO groups 2–5 PH at the national level in the United States (US). We hypothesize that WHO group 1 PH-related mortality has improved over the last two decades in comparison to WHO groups 2–5 PH. METHODS: In this study, we used data from the Centers for Disease Control and Prevention Wide-ranging Online Data for Epidemiologic Research (CDC WONDER) the underlying cause of death database to study age-standardized mortality rates related to PH in the US from 2003 to 2020. RESULTS: A total of 126,526 deaths were recorded from PH in the US between 2003 and 2020. Across the study period, PH-related ASMR increased from 17.81 per million population in 2003 to 23.89 in 2020 with a percentage change (PC) of +34%. However, there are contrasting mortality trends in WHO group 1 PH when compared to WHO groups 2–5 PH. Data demonstrated a decline in mortality from group 1 PH regardless of gender. In contrast, an increase in mortality from WHO groups 2–5 PH was observed, accounting for the major proportion of the overall PH mortality burden in recent years. CONCLUSIONS: PH-related mortality continues to an increase primarily due to increase in mortality attributed to WHO groups 2–5 PH. These findings have notable public health implications. Screening and risk assessment tools for secondary PH, risk factor modification, and novel management strategies are vital to improve outcomes. |
format | Online Article Text |
id | pubmed-10323561 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | AME Publishing Company |
record_format | MEDLINE/PubMed |
spelling | pubmed-103235612023-07-07 Pulmonary hypertension associated mortality in the United States from 2003 to 2020: an observational analysis of time trends and disparities Singh, Harpreet Agarwal, Lipisha Jani, Chinmay Bhatt, Padmanabh Hartley, Adam Shalhoub, Joseph Kurman, Jonathan S. Al Omari, Omar Ahmed, Alaaeldin Marshall, Dominic C. Salciccioli, Justin D. J Thorac Dis Original Article BACKGROUND: Pulmonary hypertension (PH) is an independent risk factor for morbidity and mortality. In the last two decades, significant advances have been made in management of World Health Organization (WHO) group 1 PH. However, there are no approved targeted pharmacotherapies for PH secondary to left-sided heart diseases or chronic hypoxic lung diseases which are thought to account for more than 70–80% of the disease burden. No recent investigation has analyzed and compared the mortality burden related to WHO group 1 PH with the mortality burden with WHO groups 2–5 PH at the national level in the United States (US). We hypothesize that WHO group 1 PH-related mortality has improved over the last two decades in comparison to WHO groups 2–5 PH. METHODS: In this study, we used data from the Centers for Disease Control and Prevention Wide-ranging Online Data for Epidemiologic Research (CDC WONDER) the underlying cause of death database to study age-standardized mortality rates related to PH in the US from 2003 to 2020. RESULTS: A total of 126,526 deaths were recorded from PH in the US between 2003 and 2020. Across the study period, PH-related ASMR increased from 17.81 per million population in 2003 to 23.89 in 2020 with a percentage change (PC) of +34%. However, there are contrasting mortality trends in WHO group 1 PH when compared to WHO groups 2–5 PH. Data demonstrated a decline in mortality from group 1 PH regardless of gender. In contrast, an increase in mortality from WHO groups 2–5 PH was observed, accounting for the major proportion of the overall PH mortality burden in recent years. CONCLUSIONS: PH-related mortality continues to an increase primarily due to increase in mortality attributed to WHO groups 2–5 PH. These findings have notable public health implications. Screening and risk assessment tools for secondary PH, risk factor modification, and novel management strategies are vital to improve outcomes. AME Publishing Company 2023-06-13 2023-06-30 /pmc/articles/PMC10323561/ /pubmed/37426148 http://dx.doi.org/10.21037/jtd-22-1468 Text en 2023 Journal of Thoracic Disease. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) . |
spellingShingle | Original Article Singh, Harpreet Agarwal, Lipisha Jani, Chinmay Bhatt, Padmanabh Hartley, Adam Shalhoub, Joseph Kurman, Jonathan S. Al Omari, Omar Ahmed, Alaaeldin Marshall, Dominic C. Salciccioli, Justin D. Pulmonary hypertension associated mortality in the United States from 2003 to 2020: an observational analysis of time trends and disparities |
title | Pulmonary hypertension associated mortality in the United States from 2003 to 2020: an observational analysis of time trends and disparities |
title_full | Pulmonary hypertension associated mortality in the United States from 2003 to 2020: an observational analysis of time trends and disparities |
title_fullStr | Pulmonary hypertension associated mortality in the United States from 2003 to 2020: an observational analysis of time trends and disparities |
title_full_unstemmed | Pulmonary hypertension associated mortality in the United States from 2003 to 2020: an observational analysis of time trends and disparities |
title_short | Pulmonary hypertension associated mortality in the United States from 2003 to 2020: an observational analysis of time trends and disparities |
title_sort | pulmonary hypertension associated mortality in the united states from 2003 to 2020: an observational analysis of time trends and disparities |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10323561/ https://www.ncbi.nlm.nih.gov/pubmed/37426148 http://dx.doi.org/10.21037/jtd-22-1468 |
work_keys_str_mv | AT singhharpreet pulmonaryhypertensionassociatedmortalityintheunitedstatesfrom2003to2020anobservationalanalysisoftimetrendsanddisparities AT agarwallipisha pulmonaryhypertensionassociatedmortalityintheunitedstatesfrom2003to2020anobservationalanalysisoftimetrendsanddisparities AT janichinmay pulmonaryhypertensionassociatedmortalityintheunitedstatesfrom2003to2020anobservationalanalysisoftimetrendsanddisparities AT bhattpadmanabh pulmonaryhypertensionassociatedmortalityintheunitedstatesfrom2003to2020anobservationalanalysisoftimetrendsanddisparities AT hartleyadam pulmonaryhypertensionassociatedmortalityintheunitedstatesfrom2003to2020anobservationalanalysisoftimetrendsanddisparities AT shalhoubjoseph pulmonaryhypertensionassociatedmortalityintheunitedstatesfrom2003to2020anobservationalanalysisoftimetrendsanddisparities AT kurmanjonathans pulmonaryhypertensionassociatedmortalityintheunitedstatesfrom2003to2020anobservationalanalysisoftimetrendsanddisparities AT alomariomar pulmonaryhypertensionassociatedmortalityintheunitedstatesfrom2003to2020anobservationalanalysisoftimetrendsanddisparities AT ahmedalaaeldin pulmonaryhypertensionassociatedmortalityintheunitedstatesfrom2003to2020anobservationalanalysisoftimetrendsanddisparities AT marshalldominicc pulmonaryhypertensionassociatedmortalityintheunitedstatesfrom2003to2020anobservationalanalysisoftimetrendsanddisparities AT salcicciolijustind pulmonaryhypertensionassociatedmortalityintheunitedstatesfrom2003to2020anobservationalanalysisoftimetrendsanddisparities |